Highlights

• CT:VQ receives CE Mark certification enabling EU commercial deployment
• Completed $83M institutional placement at $5.90/share to fund European expansion
• World's first and only non-contrast CT-based ventilation-perfusion imaging solution
• Pro forma cash balance of $289M provides substantial runway for commercialization
• Deployed at six leading US Academic Medical Centers with Mayo Clinic using CT:VQ

4DMedical Limited (ASX:4DX) announced a significant regulatory milestone on March 27, 2026, receiving CE Mark certification for CT:VQ, its proprietary ventilation-perfusion imaging technology. Simultaneously, the company completed an $83 million institutional placement at $5.90 per share, demonstrating strong investor demand for the company's European expansion strategy.

CT:VQ represents a transformative technology in respiratory imaging. By enabling clinicians to visualize lung ventilation and perfusion without requiring contrast injection, CT:VQ addresses a critical clinical need while reducing procedural complexity and risk for patients.

The CE Mark approval opens the entire European Union market, home to 450+ million people served by one of the world's most advanced healthcare systems. For investors, the question becomes: can 4DMedical successfully commercialize CT:VQ in Europe while maintaining momentum in the US, or will execution challenges limit upside from this regulatory catalyst?

About the Company

Global Leader in Functional Respiratory Imaging

4DMedical is an advanced medical imaging technology company headquartered in Melbourne, Australia, with US operations in Los Angeles. The company develops software and imaging solutions for respiratory assessment and disease monitoring.

The company offers a comprehensive portfolio of lung imaging and analysis products including XV LVAS, CT LVAS, CT:VQ, Functional Lung Density Analysis, Lung Nodules, Coronary Artery Calcium assessment, and Pulmonary Hypertension Analysis tools. CT:VQ represents the flagship innovation and primary growth driver.

4DMedical is publicly listed on the ASX and has successfully raised over $100 million in equity financing. The company maintains strategic partnerships with leading healthcare institutions and device manufacturers.

Why the Stock is Moving

CE Mark Approval: Europe's Gateway Opens

The CE Mark certification is 4DMedical's first major regulatory approval in Europe. CE Mark, equivalent to FDA approval in the US, allows companies to freely market medical devices across all European Union member states plus Iceland, Liechtenstein, and Norway.

This approval is particularly significant because the European respiratory imaging market is substantial and mature. An estimated 400,000 ventilation-perfusion scans are performed annually across the EU, representing meaningful addressable volume for CT:VQ.

The $83 million institutional placement at $5.90 per share demonstrates strong investor confidence. The placement price represents a 6.1% discount to the prior day's closing price and 12.3% premium to the 5-day volume-weighted average price, a typical valuation structure for large institutional raises.

Combined with a pro forma cash balance of $289 million as of December 31, 2025, 4DMedical has exceptional financial capacity to fund European market entry, US clinical deployments, and additional R&D initiatives without requiring additional capital raises for several years.

Industry Trends

Medical Imaging: Shift Toward Functional Assessment

The global medical imaging market is undergoing a fundamental shift from anatomical imaging (visualizing structure) toward functional imaging (understanding physiology). CT:VQ exemplifies this trend by providing functional respiratory assessment without traditional anatomical modalities.

Respiratory imaging demand is accelerating. Post-COVID, healthcare systems worldwide have heightened focus on lung disease diagnosis and monitoring. Chronic obstructive pulmonary disease, pulmonary hypertension, and interstitial lung disease represent enormous global patient populations requiring advanced diagnostic capabilities.

Contrast-free imaging is increasingly preferred due to renal safety, allergic reaction risks, and patient convenience. 4DMedical's non-contrast CT:VQ approach addresses clinician and patient preferences, differentiating the technology from traditional contrast-based ventilation-perfusion methods.

Hospital imaging infrastructure consolidation continues globally. Larger healthcare systems increasingly standardize on unified imaging platforms. 4DMedical's integration partnerships with major CT manufacturers provide distribution advantages.

Financial Performance

Exceptional Cash Position and Capital Efficiency

The $83 million placement, combined with the prior $289 million cash balance, positions 4DMedical with $372 million in total liquid capital (before placement execution costs). This represents extraordinary financial strength for a company at the commercialization stage.

4DMedical maintains multiple revenue streams from its imaging software portfolio, though revenue remains modest relative to cash burn. Operating losses continue as the company invests heavily in R&D, regulatory submissions, and commercialization infrastructure.

The placement price of $5.90 per share values the company at approximately $3.6 billion (fully diluted post-placement). This valuation reflects the substantial market opportunity for CT:VQ and the company's track record of regulatory approvals across multiple jurisdictions.

Investors should monitor revenue growth trajectory carefully. As CT:VQ commercialization accelerates in the US and now Europe, cash flow improvement and progression toward profitability become critical valuation inflection points. Current high cash position provides runway, but ultimate success depends on revenue generation, not just capital conservation.

Investment Risks

European Commercialization Execution

CE Mark approval eliminates regulatory barriers to European deployment, but it creates new commercialization challenges. Building healthcare provider relationships, hospital procurement engagement, and clinical training programs across 27 EU member states requires sophisticated market access capabilities.

European healthcare procurement is more centralized and bureaucratic than the US. Some EU countries have national health technology assessment requirements beyond CE Mark approval. Reimbursement timelines are often measured in years, not months.

Competitive Pressure and Market Share Assumptions

Traditional nuclear medicine ventilation-perfusion imaging remains entrenched in many European institutions. Displacing established workflows requires demonstrating clear clinical and economic advantages. 4DMedical's value proposition depends on adoption at scale.

Larger diagnostic imaging companies may develop competing non-contrast VQ solutions. 4DMedical's current monopoly position in this technology space could erode if competitors successfully develop alternative approaches. First-mover advantage may be temporary.

Valuation Sensitivity

At a $3.6 billion valuation, 4DMedical's share price is highly sensitive to commercialization timeline slippage or competitive developments. The placement at $5.90 represents peak confidence. Any negative developments could trigger material share price weakness.

Future Growth Drivers

European Hospital Deployment Acceleration

The immediate growth driver is CT:VQ adoption across European hospitals. Each hospital deployment generates recurring software licensing and analysis fees. If 4DMedical achieves deployment in 20-30% of major European hospitals within 3-5 years, revenue growth would accelerate dramatically.

Additional FDA applications beyond CT:VQ are in development, expanding the US addressable market. Lung nodule detection, density analysis, and pulmonary hypertension assessment all represent potential revenue streams.

International expansion beyond EU and US, including Canada, Australia, and Asia-Pacific markets, could follow successful European and US commercialization. Each geographic market represents multiple millions in potential annual revenue.

Analyst Outlook

Analyst coverage of 4DMedical has been increasing as the company approaches commercialization inflection points. The CE Mark approval and Mayo Clinic deployment represent significant validation milestones.

Most analysts view 4DMedical favorably, citing the massive addressable market, unique technology position, and strong balance sheet. However, near-term share price appreciation may be limited given the recent large institutional placement. Investors should assess whether current valuation adequately compensates for commercialization risks.

Key analyst metrics to monitor include hospital deployment counts, CT:VQ utilization rates, reimbursement progress, and cash burn relative to revenue generation. Quarterly updates on these metrics will drive near-term share price movement.

Long-Term Perspective

Integration with major CT equipment manufacturers accelerates hospital adoption. Hospitals standardizing on specific CT platforms benefit from optimized software integration and technical support. 4DMedical partnerships with CT manufacturers should yield growing deployment opportunities as awareness spreads among hospital procurement teams.

The Mayo Clinic deployment of CT:VQ represents significant third-party validation. Mayo Clinic is recognized globally as a leader in diagnostic innovation and clinical excellence. Its adoption of CT:VQ creates powerful reference point for other academic medical centers evaluating advanced imaging solutions.

Hospital capital budgets for imaging equipment remain robust across Europe and the US. Imaging departments actively seek advanced diagnostic capabilities that differentiate their institutions and attract referring physicians. 4DMedical's technology positions well to capture capital budget allocation from hospital imaging departments.

Healthcare procurement officers across Europe increasingly prioritize imaging solutions that reduce patient risk and improve clinical outcomes. CT:VQ's non-contrast approach directly addresses procurement priorities around patient safety and clinical efficacy. This alignment should accelerate adoption conversations with hospital imaging departments.

Market research analysts covering medical imaging have been bullish on 4DMedical since FDA 510(k) clearance for CT:VQ in the US. The CE Mark approval for Europe removes the final major regulatory hurdle, positioning the company for global commercialization.

From a 5-10 year perspective, 4DMedical could become a multi-billion-dollar revenue medical imaging company if CT:VQ achieves mainstream adoption across US, European, and Asian markets. The total addressable market for respiratory imaging is enormous relative to current revenues.

Profitability appears achievable within 3-5 years if deployment accelerates as management guidance suggests. Positive cash flow generation would eliminate capital raise dependency and provide substantial shareholder value.

Long-term value creation scenarios include: (1) standalone profitability and positive cash generation, (2) acquisition by a larger medical device company at a premium, or (3) global expansion with multi-market deployment scaling. All three scenarios remain achievable.

Investors should maintain conviction through inevitable commercialization volatility. Medical device adoption timelines are often longer than expected. However, 4DMedical's unique technology, regulatory approvals, and financial strength position the company well for long-term value creation.

Conclusion

4DMedical stands at an exciting inflection point. CE Mark approval combined with the $83 million capital raise create momentum for European market entry. The company has the capital, technology, and regulatory approvals necessary to succeed.

However, the $3.6 billion valuation leaves limited room for error. Commercialization execution must accelerate and deployment rates must expand rapidly to justify current valuation. Investors should monitor hospital deployment counts and utilization metrics closely.

For growth-focused investors with conviction in medical imaging innovation, 4DMedical offers exposure to a transformative technology addressing a substantial global market need. The next 12-24 months will determine whether CE Mark approval translates into meaningful revenue acceleration. Monitor quarterly results carefully and reassess conviction if deployment momentum disappoints.